Zacks Investment Research lowered shares of Pharming Group (OTCMKTS:PHGUF) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning.

According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “

A number of other research firms have also weighed in on PHGUF. ValuEngine lowered shares of Pharming Group from a hold rating to a sell rating in a report on Friday, December 1st. HC Wainwright reissued a buy rating on shares of Pharming Group in a report on Thursday, October 26th.

Shares of Pharming Group (PHGUF) opened at $1.48 on Tuesday. Pharming Group has a 1-year low of $0.25 and a 1-year high of $1.58. The company has a debt-to-equity ratio of 11.72, a current ratio of 1.77 and a quick ratio of 1.27.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/09/pharming-group-phguf-downgraded-by-zacks-investment-research-to-hold.html.

Pharming Group Company Profile

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related stocks with our FREE daily email newsletter.